ID   A-673
AC   CVCL_0080
SY   A673; RMS 1598; RMS1598
DR   BTO; BTO:0003768
DR   CLO; CLO_0001605
DR   CLO; CLO_0001606
DR   EFO; EFO_0002106
DR   CLDB; cl166
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1598
DR   ATCC; CRL-7910
DR   BioGRID_ORCS_Cell_line; 160
DR   BioSample; SAMN03473282
DR   BioSample; SAMN10987881
DR   cancercelllines; CVCL_0080
DR   CCRID; 3101HUMTCHu223
DR   Cell_Model_Passport; SIDM00848
DR   ChEMBL-Cells; CHEMBL3307384
DR   ChEMBL-Targets; CHEMBL614517
DR   CLS; 300454
DR   Cosmic; 684052
DR   Cosmic; 1091064
DR   Cosmic; 1097757
DR   Cosmic; 1388901
DR   Cosmic; 1718108
DR   Cosmic; 1995338
DR   Cosmic; 2228213
DR   Cosmic; 2250469
DR   Cosmic; 2294580
DR   Cosmic-CLP; 684052
DR   DepMap; ACH-000052
DR   ECACC; 85111504
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS304EKV
DR   ENCODE; ENCBS385OLC
DR   ENCODE; ENCBS615MBV
DR   ENCODE; ENCBS790NPQ
DR   GDSC; 684052
DR   GEO; GSM510002
DR   GEO; GSM827304
DR   GEO; GSM886859
DR   GEO; GSM887924
DR   GEO; GSM1669590
DR   GEO; GSM1676306
DR   GEO; GSM1701623
DR   GEO; GSM1899422
DR   IARC_TP53; 705
DR   IARC_TP53; 21168
DR   IGRhCellID; A673
DR   KCLB; 21598
DR   LiGeA; CCLE_182
DR   LINCS_LDP; LCL-1410
DR   Lonza; 1455
DR   PharmacoDB; A673_49_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0080
DR   PubChem_Cell_line; CVCL_0080
DR   Wikidata; Q54606055
RX   DOI=10.5282/edoc.27750;
RX   PubMed=212188;
RX   PubMed=327080;
RX   PubMed=375235;
RX   PubMed=3335022;
RX   PubMed=4357758;
RX   PubMed=6256643;
RX   PubMed=6825208;
RX   PubMed=6954533;
RX   PubMed=8275086;
RX   PubMed=8378080;
RX   PubMed=10379870;
RX   PubMed=11423975;
RX   PubMed=12068308;
RX   PubMed=12606131;
RX   PubMed=14697648;
RX   PubMed=16888811;
RX   PubMed=17431109;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21822310;
RX   PubMed=22142829;
RX   PubMed=22282976;
RX   PubMed=22460905;
RX   PubMed=23882450;
RX   PubMed=24312454;
RX   PubMed=24758355;
RX   PubMed=25010205;
RX   PubMed=25223734;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26351324;
RX   PubMed=26428435;
RX   PubMed=26589293;
RX   PubMed=26979953;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30879952;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=34413129;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=16888811); 25 hours (PubMed=24312454); 28 hours (PubMed=25984343).
CC   HLA typing: A*01:01,02:01; B*07:02,07:02; C*07:02,07:02; DQB1*03:02,03:02; DRB1*15:01,14:76 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; PubMed=25010205; PubMed=25223734; ATCC).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975; PubMed=25010205; PubMed=25485619).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=22142829; PubMed=25010205; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala119Glnfs*5 (c.353_354dupCA) (c.354_355insCA); Zygosity=Homozygous (PubMed=8378080; PubMed=19787792; PubMed=25010205; PubMed=25223734; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: H3K9me3 ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.54%; Native American=0%; East Asian, North=1.77%; East Asian, South=0%; South Asian=0%; European, North=69.11%; European, South=28.57% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7910; true.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=19787792; PubMed=24312454; PubMed=25010205; PubMed=25877200; PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,13
ST   D16S539: 11
ST   D18S51: 13,16
ST   D19S433: 13,14
ST   D21S11: 29,30.2
ST   D2S1338: 16,21
ST   D3S1358: 14
ST   D5S818: 11,12 (ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=24312454; PubMed=25010205; PubMed=25877200; PubMed=30879952)
ST   D5S818: 12 (PubMed=19787792)
ST   D7S820: 10,12
ST   D8S1179: 11,13
ST   FGA: 19,20
ST   Penta D: 12,13
ST   Penta E: 10,13
ST   SE33: 30.2,32.2
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=212188;
RA   Todaro G.J., De Larco J.E.;
RT   "Growth factors produced by sarcoma virus-transformed cells.";
RL   Cancer Res. 38:4147-4154(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
//
RX   PubMed=6256643; DOI=10.1038/288724a0;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.;
RT   "Defective repair of alkylated DNA by human tumour and
RT   SV40-transformed human cell strains.";
RL   Nature 288:724-727(1980).
//
RX   PubMed=6825208; DOI=10.1093/carcin/4.2.199;
RA   Yarosh D.B., Foote R.S., Mitra S., Day R.S. III;
RT   "Repair of O6-methylguanine in DNA by demethylation is lacking in Mer-
RT   human tumor cell strains.";
RL   Carcinogenesis 4:199-205(1983).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
//
RX   PubMed=10379870; DOI=10.1002/(SICI)1098-2264(199907)25:3<241::AID-GCC6>3.0.CO;2-7;
RA   Roberts I., Wienberg J., Nacheva E., Grace C., Griffin D.K., Coleman N.;
RT   "Novel method for the production of multiple colour chromosome paints
RT   for use in karyotyping by fluorescence in situ hybridisation.";
RL   Genes Chromosomes Cancer 25:241-250(1999).
//
RX   PubMed=11423975; DOI=10.1038/sj.onc.1204437;
RA   Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V.,
RA   Weissman B.E., Delattre O.;
RT   "Analysis of the expression of cell cycle regulators in Ewing cell
RT   lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.";
RL   Oncogene 20:3258-3265(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12606131; DOI=10.1016/S0165-4608(02)00670-2;
RA   Martinez-Ramirez A., Rodriguez-Perales S., Melendez B.,
RA   Martinez-Delgado B., Urioste M., Cigudosa J.C., Benitez J.;
RT   "Characterization of the A673 cell line (Ewing tumor) by molecular
RT   cytogenetic techniques.";
RL   Cancer Genet. Cytogenet. 141:138-142(2003).
//
RX   PubMed=14697648; DOI=10.1016/S0165-4608(03)00209-7;
RA   Coleman N., Roberts I.;
RT   "Re: Characterization of the A673 cell line (Ewing tumor) by molecular
RT   cytogenetic techniques.";
RL   Cancer Genet. Cytogenet. 148:86-86(2004).
//
RX   PubMed=16888811; DOI=10.1002/jcb.21073;
RA   Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F.,
RA   Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C.,
RA   Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.;
RT   "Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged
RT   sarcoma cell lines correlates with mutated p53.";
RL   J. Cell. Biochem. 100:339-348(2007).
//
RX   PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729;
RA   Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C.,
RA   Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.;
RT   "Levels of p27(kip1) determine Aplidin sensitivity.";
RL   Mol. Cancer Ther. 6:1310-1316(2007).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:E80060-E80060(2013).
//
RX   PubMed=24758355; DOI=10.1186/1471-2407-14-281;
RA   Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R.,
RA   Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.;
RT   "Levels of active tyrosine kinase receptor determine the tumor
RT   response to Zalypsis.";
RL   BMC Cancer 14:281.1-281.10(2014).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26979953; DOI=10.1073/pnas.1521251113;
RA   Town J., Pais H., Harrison S., Stead L.F., Bataille C., Bunjobpol W.,
RA   Zhang J., Rabbitts T.H.;
RT   "Exploring the surfaceome of Ewing sarcoma identifies a new and unique
RT   therapeutic target.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:3603-3608(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=34413129; DOI=10.1158/1535-7163.MCT-21-0089;
RA   Gartrell J., Mellado-Largarde M., Clay M.R., Bahrami A., Sahr N.A.,
RA   Sykes A., Blankenship K., Hoffmann L., Xie J., Cho H.P., Twarog N.,
RA   Connelly M., Yan K.-K., Yu J.-Y., Porter S.N., Pruett-Miller S.M.,
RA   Neale G., Tinkle C.L., Federico S.M., Stewart E.A., Shelat A.A.;
RT   "SLFN11 is widely expressed in pediatric sarcoma and induces variable
RT   sensitization to replicative stress caused by DNA-damaging agents.";
RL   Mol. Cancer Ther. 20:2151-2165(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//